

CLAIMS

1. A pharmaceutical composition comprising an alpha-adrenoceptor antagonist, a 5-HT₄-receptor antagonist and a pharmaceutically acceptable carrier.
5
2. A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is non-selective.
3. A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selective for the alpha₁-receptor.
10
4. A pharmaceutical composition as claimed in claim 1 wherein the alpha-adrenoceptor antagonist is selected from abanoquil, alfuzosin, indoramin, tamsulosin, doxazosin, parvosin, terazosin, abanoquil, prazosin and pharmaceutically acceptable salts thereof.
15
5. A pharmaceutical compositions as claimed in any of claims 1 to 4 wherein the 5-HT₄-receptor antagonist is selective for the 5-HT₄-receptor.
6. A pharmaceutical composition as claimed in any of claims 1 to 4 wherein the 5-HT₄-receptor antagonist is selected from SB 205800, SB 203186, R50595, GR 113808, GR 125487, GR 138897, LY-353433, DAU 6285, SDZ 205-557, RS 23597-190, or (3S-trans)-4-(4-[[[(8-chloro-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin-1-yl)-butyric acid and pharmaceutically acceptable salts thereof.
20
25
7. A pharmaceutical composition as claimed in claim 6 wherein the 5-HT₄-receptor antagonist is (3S-trans)-4-(4-[[[(8-chloro-3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carbonyl)-amino]-methyl]-3-hydroxy-piperidin-1-yl)-butyric acid and pharmaceutically acceptable salts thereof.
30
8. An alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist for use as a medicament.
9. Use of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms.
35

10. Use of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with overactive bladder.
- 5 11. Use of an alpha-adrenoceptor antagonist in combination with a 5-HT₄-receptor antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with mild to moderate benign prostatic hyperplasia in mammals.
- 10 12. A product comprising a first pharmaceutically acceptable composition containing an alpha-adrenoceptor antagonist and a second pharmaceutically acceptable composition a 5-HT₄-receptor antagonist for use as a combined preparation for simultaneous or sequential use in treating the lower urinary tract symptoms associated with overactive bladder or benign prostatic hyperplasia in mammals.